The Filing Desk

Fate Therapeutics vs Whitehawk Therapeutics

Fate Therapeutics FATE · Whitehawk Therapeutics WHWK · Biotechnology

Whitehawk Therapeutics reported revenue of $7 million in fiscal 2025, about the same as Fate Therapeutics' $7 million in fiscal 2025. Fate Therapeutics' revenue fell 51.2% in its latest year, and Whitehawk Therapeutics' fell 72.5%. Fate Therapeutics had an operating margin of -2222.4%, against -1601.1% at Whitehawk Therapeutics. Free cash flow was −$112 million at Fate Therapeutics and −$98 million at Whitehawk Therapeutics.

Side by side

Fate TherapeuticsWhitehawk Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$7M$7M
Revenue growth−51.2%−72.5%
Revenue growth a year, last 5 years−26.8%−12.7%
Gross margin—89.4%
Operating margin−2,222.4%−1,601.1%
Net margin−2,051.1%−288.3%
Free cash flow−$112M−$98M
Free cash flow margin−1,685.8%−1,371.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.5%129.0%
Last close$1.01$3.12
P/E at the last close——
Insider trades, last 12 monthssold $322,862sold $2.6 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Fate TherapeuticsWhitehawk Therapeutics
Operating margin
Percent of revenue
Fate TherapeuticsWhitehawk Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fate TherapeuticsWhitehawk Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fate Therapeutics and Whitehawk Therapeutics pages.